Skip to content

Uncategorized

Prebiotic Reduces Body Fat and Alters Intestinal Microbiota in Overweight or Obese Children

Published in Primary Care and

1 other channel

Journal Scan / Research · June 21, 2017

Gastroenterology

TAKE-HOME MESSAGE

  • Children aged 7 to 12 years with overweight or obesity were randomized to receive the prebiotic oligofructose-enriched inulin (OI) or maltodextrin placebo daily for 16 weeks. Children receiving OI had a significant decrease in body weight z-score, percent body fat, and percent trunk fat; those taking placebo had a small increase in body weight z-score and percent body fat, with a small decrease in percent trunk fat. Levels of interleukin 6 (IL-6) were reduced by 15% from baseline in children given OI compared with a 25% increase in the placebo group. Children in the OI group had a significant decrease in serum triglycerides of 19%. Analysis of the intestinal microbiota revealed a significant increase in Bifidobacterium spp. and a decrease in Bacteroides vulgatus in the OI group over the course of the study period.
  • In children with overweight or obesity, the use of a daily prebiotic altered the intestinal microbiota and led to reductions in body weight and body fat as well as reductions in IL-6 levels.

Primary Care

Written by
David Rakel MD, FAAFP

This small study of overweight children found that taking a prebiotic (oligofructose-enriched inulin, 8 g daily for 16 weeks) was associated with less weight gain than placebo and resulted in a shift in the microbiome to include more bifidobacteria. Bifidobacteria is established with breastfeeding and is associated with less weight gain (see graphic 1 for the results of the study).
Prebiotics and Child Weight

But, before you Google “oligofructose-enriched inulin” for a supplement to recommend to your overweight patients, remember that this is simply a fiber combined with short-chain sugars found in plants. A prebiotic is generally a soluble fiber that bypasses absorption in the upper intestinal track, passing into the colon and providing fuel for bacterial growth and fermentation (gas; see graphic 2).
FODMaPS

Foods rich in inulin include whole grains, onions, garlic, leeks, Jerusalem artichoke, and chicory root. Other prebiotic fibers that would likely work include psyllium, ground flax seed, and guar gum. The good news is that, other than gas and bloating, these products are very safe and may promote the establishment of a healthy microbiome at an early age, which may help with weight management as the child grows into an adult.

Abstract

This article is open access.

Access this article now

BACKGROUND & AIMS

It might be possible to manipulate the intestinal microbiota with prebiotics or other agents to prevent or treat obesity. However, little is known about the ability of prebiotics to specifically modify gut microbiota in children with overweight/obesity or reduce body weight. We performed a randomized controlled trial to study the effects of prebiotics on body composition, markers of inflammation, bile acids in fecal samples, and composition of the intestinal microbiota in children with overweight or obesity.

METHODS

We performed a single-center, double-blind, placebo-controlled, trial of 2 separate cohorts (March 2014 and August 2014) at the University of Calgary in Canada. Participants included children, 7 – 12 years old, with overweight or obesity (>85th percentile of body mass index) but otherwise healthy. Participants were randomly assigned to groups given either oligofructose-enriched inulin (OI, 8 g/day; n=22) or maltodextrin placebo (isocaloric dose, controls; n=20) once daily for 16 weeks. Fat mass and lean mass were measured using dual-energy-x-ray absorptiometry. Height, weight, and waist circumference were measured at baseline and every 4 weeks thereafter. Blood samples were collected at baseline and 16 weeks, and analyzed for lipids, cytokines, lipopolysaccharide, and insulin. Fecal samples were collected at baseline and 16 weeks; bile acids were profiled using high-performance liquid chromatography and the composition of the microbiota was analyzed by 16S rRNA sequencing and quantitative PCR. The primary outcome was change in percent body fat from baseline to 16 weeks.

RESULTS

After 16 weeks, children who consumed OI had significant decreases in body weight z-score (decrease of 3.1%), percent body fat (decrease of 2.4%), and percent trunk fat (decrease of 3.8%) compared to children given placebo (increase of 0.5%, increase of 0.05%, and decrease of 0.3%, respectively). Children who consumed OI also had a significant reduction in level of interleukin 6 (IL6) from baseline (decrease of 15%) compared with the placebo group (increase in 25%). There was a significant decrease in serum triglycerides (decrease of 19%) in the OI group. Quantitative PCR showed a significant increase in Bifidobacterium spp. in the OI group compared with controls. 16S rRNA sequencing revealed significant increases in species of the genus Bifidobacterium and decreases in Bacteroides vulgatus within the group who consumed OI. In fecal samples, levels of primary bile acids increased in the placebo group but not in the OI group over the 16-week study period.

CONCLUSIONS

In a placebo-controlled, randomized trial, we found a prebiotic (OI) to selectively alter the intestinal microbiota and significantly reduce body weight z-score, percent body fat, percent trunk fat, and serum level of IL6 in children with overweight or obesity.

Acupuncture Found to Be an Effective Analgesia Option in ER

Published in Primary Care

News · June 20, 2017

May provide a safe alternative to opioids, researchers say

Acupuncture is a safe and effective alternative to pain medications for some emergency department patients, according to a study published in the June 19 issue of the Medical Journal of Australia.

MONDAY, June 19, 2017 (HealthDay News) — Acupuncture is a safe and effective alternative to pain medications for some emergency department patients, according to a study published in the June 19 issue of the Medical Journal of Australia.

The study — billed as the world’s largest randomized, controlled trial of acupuncture in the emergency department — included 528 patients. The study participants were seen at four Australian emergency departments for acute low back pain, migraines, or ankle sprains. Patients who said their level of pain was at least 4 on a 10-point scale received one of three treatments: acupuncture alone; acupuncture with pharmacotherapy; or pharmacotherapy alone.

One hour after treatment, 36.9 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale. More than 80 percent still had a pain rating of at least 4, the researchers found. But two days later, most patients were satisfied. Overall, 82.8 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with 80.8 percent in the combined group and 78.2 percent in the pharmacotherapy-alone group.

“Emergency nurses and doctors need a variety of pain-relieving options when treating patients, given the concerns around opioids such as morphine, which carry the risk of addiction when used long-term,” lead investigator Marc Cohen, M.B.B.S., Ph.D., a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia, said in a university news release.

Neuropathy associated with gluten sensitivity

J Neurol Neurosurg Psychiatry. 2006 Nov; 77(11): 1262–1266.
Published online 2006 Jul 11. doi:  10.1136/jnnp.2006.093534
 
M Hadjivassiliou, R A Grünewald, R H Kandler, A K Chattopadhyay, J A Jarratt, D S Sanders, B Sharrack, S B Wharton, and G A B Davies‐Jones

Abstract

Objectives

To prospectively study the clinical, neurophysiological and neuropathological characteristics of axonal neuropathies associated with positive antigliadin antibodies and the prevalence of such neuropathies in a cohort of patients with sporadic axonal neuropathy.

Methods

Prospective screening (using antigliadin, antiendomysium and tissue transglutaminase antibodies) of patients with peripheral neuropathy attending a neurology clinic.

Results

215 patients with axonal neuropathy were screened. 141 patients had symmetrical sensorimotor neuropathy, 47 had mononeuropathy multiplex, 17 had motor neuropathy and 10 had small‐fibre neuropathy. Despite extensive investigations of the 215 patients, 140 had idiopathic neuropathy. Positive immunoglobulin (Ig)G with or without IgA antigliadin antibodies was found in 34% (47/140) of the patients with idiopathic neuropathy. This compares with 12% prevalence of these antibodies in the healthy controls. The prevalence of coeliac disease as shown by biopsy in the idiopathic group was at least 9% as compared with 1% in the controls. The clinical features of 100 patients (47 from the prevalence study and 53 referred from elsewhere) with gluten neuropathy included a mean age at onset of 55 (range 24–77) years and a mean duration of neuropathy of 9 (range 1–33) years. Gluten‐sensitive enteropathy was present in 29% of patients. The human leucocyte antigen types associated with coeliac disease were found in 80% of patients.

Conclusions

Gluten sensitivity may be aetiologically linked to a substantial number of idiopathic axonal neuropathies.

Gluten sensitivity is a state of heightened immunological responsiveness to ingested gluten in genetically susceptible people.1 It represents a spectrum of diverse manifestations, one of which is gluten‐sensitive enteropathy. The term coeliac disease should now be restricted to describe gluten‐sensitive enteropathy (triad of villous atrophy, crypt hyperplasia and increased intraepithelial lymphocytes on histological examination of small‐bowel mucosa). The term gluten sensitivity describes a spectrum of diseases having in common an immune response to the ingestion of gluten, but with diverse manifestations such as an enteropathy (coeliac disease), dermatopathy (dermatitis herpetiformis) and neurological disorders (eg, gluten ataxia and neuropathy).2 Not surprisingly, the common aetiological trigger (gluten) means that these diseases overlap considerably. For example, most patients with dermatitis herpetiformis also have coeliac disease, as do a third of patients with gluten ataxia.3 Similarly, 8% of patients with established coeliac disease develop neurological manifestations.4

A review of all published papers from 1964 to 2000 (single and multiple case reports) of 83 patients with coeliac disease who then develop neurological illness shows that the most common neurological entities encountered were ataxia (n = 29) and peripheral axonal neuropathy (n = 29).5 We have previously reported that neurological manifestations can present even in the absence of an enteropathy. The most common neurological dysfunction encountered was ataxia (gluten ataxia) and peripheral axonal neuropathy.6,7 Of 28 patients with axonal peripheral neuropathy, 13 had positive antigliadin antibodies.6 Most neuropathies encountered were symmetrical sensorimotor axonal in type. There have since been additions to the literature on neuropathy and coeliac disease. One such study showed that among patients with established coeliac disease on a gluten‐free diet, 23% had evidence of axonal peripheral neuropathy.8 Another study found that 2.5% of all patients with neuropathy had coeliac disease.9 The figure was higher at 8% when patients with symptoms of neuropathy but normal neurophysiological assessment were included.9 Given that 1% of the healthy population has coeliac disease10 with no gastrointestinal symptoms and as many as 12% may have serological evidence of gluten sensitivity, the prevalence of gluten sensitivity‐related neuropathy in patients with sporadic axonal neuropathy merits more detailed investigation.

The first aim of this 10‐year study was to study prospectively the prevalence of gluten sensitivity and coeliac disease (using antigliadin, antiendomysium and transglutaminase antibodies as well as duodenal biopsies) in a large number of patients with axonal neuropathies. The second aim was to characterise gluten neuropathy in clinical, neurophysiological and neuropathological terms.

Go to:

Patients and methods

Patient selection

All patients with clinical and neurophysiological evidence of axonal neuropathy were consecutively recruited over a period of 10 years (1994–2004) from a general neurology clinic at the Department of Clinical Neurology, The Royal Hallamshire Hospital, Sheffield, UK. The consultants running the clinic (initially GABD‐J and then MH) have a particular interest in patients with chronic idiopathic axonal neuropathy, and such patients are followed up regularly. Patients with a family history of neuropathy or positive genetic testing for familial neuropathies were excluded, as were patients with demyelinating neuropathies such as Guillain–Barré syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathies with conduction block. Tertiary referrals of patients with the diagnosis of gluten sensitivity and peripheral neuropathy referred to the gluten sensitivity/neurology clinic by consultant neurologists from Sheffield and other UK neurology centres were not included in the prevalence part of the study, but were included for the purpose of defining the clinical characteristics. For the estimation of prevalence of antigliadin antibodies and coeliac disease in the healthy population of the region (similar demographic characteristics), a separate parallel study (1999–2001) was conducted and the results have been published.10 The data from this study were used for the comparison of the prevalence of antigliadin antibodies and coeliac disease between healthy controls and patients with neuropathy.

Investigations of peripheral neuropathy

As part of the screening process for the aetiology of neuropathy, all patients underwent the following investigations at least once: full‐blood count, erythrocyte sedimentation rate, vitamin B12, red cell or serum folate, urea and electrolytes, liver function tests, thyroid function tests, random blood sugar, glycosylated haemoglobin (in selected cases, glucose tolerance test), serum angiotensin‐converting enzyme, immunoglobulins and electrophoresis (with immunofixation), antinuclear antibodies, double‐stranded DNA, extractable nuclear antibodies, antigliadin antibodies (IgG and IgA), IgA endomysium antibodies, IgA tissue transglutaminase antibodies (the antiendomysium and tissue transglutaminase assays became available half way through the study, which is why not all patients were tested at baseline), rheumatoid factor, antinuclear cytoplasmic antibodies and chest radiograph. Additional investigations were carried out if clinically indicated, and included borrelia serology, hepatitis B and C and HIV serology, complement levels, cryoglobulins, vitamins B1, B6 and E, paraneoplastic antibodies (Hu, Yo and Ri), lead levels, abdominal ultrasound scan, sural‐nerve biopsy, abdominal and chest computed tomography scan, skeletal survey, bone marrow examination and positron emission tomography scan.

Additional investigations for patients with neuropathy and gluten sensitivity

All patients with positive antigliadin antibodies (IgG or IgA) irrespective of the presence of antiendomysium and tissue transglutaminase antibodies were offered duodenal biopsy. Specimens were taken from the distal duodenum using biopsy forceps, through a conventional forward‐viewing endoscope (Key‐Med, Southend, UK). Four biopsy specimens were taken from the third part of the duodenum. The presence of gluten‐sensitive enteropathy was established by histological examination for evidence of crypt hyperplasia, villous atrophy and increase in intraepithelial lymphocyte count.11

Neurophysiological assessments

Nerve conduction studies and electromyography were carried out at least once in all patients where clinical evaluation suggested a diagnosis of peripheral neuropathy. All patients included in this study had evidence of axonal peripheral neuropathy on neurophysiological assessments (generalised sensory or motor peripheral neuropathy, mononeuropathy multiplex or small‐fibre neuropathy). Sensory and motor nerve conduction studies and EMG were carried out using standard techniques. Nerve conduction study results were usually deemed abnormal if values fell outside 99% confidence limits, but allowance was made in interpreting values with respect to age of the patient. Where nerve conduction studies were normal and the clinical features were suspicious of small‐fibre involvement, thermal threshold testing was performed. Thermal threshold results were considered to be abnormal if they fell outside 99% confidence limits obtained from age‐matched healthy controls.

Go to:

Results

Prevalence

A total of 215 patients with axonal neuropathy participated in this study. Of these 141 had symmetrical sensorimotor axonal neuropathy, 47 had mononeuropathy multiplex, 17 had motor neuropathy and 10 had small‐fibre neuropathy.

After investigations, the aetiology of neuropathy was established in some patients as follows: diabetes mellitus was the cause of neuropathy in 24 of 215 (11%) patients (7 had type 1 and 17 had type 2 diabetes). In 16 of 215 (7%) patients, a connective tissue disease or vasculitis was confirmed to be the aetiological factor. A paraneoplastic neuropathy was diagnosed in 9 (4%) patients. Low vitamin B12 was found in 9 (4%) patients. Cases of monoclonal gammopathy of undetermined significance (n = 5, 2%), excessive alcohol intake (n = 4, 2%), drug related (n = 3, 2 amiodarone, 1 phenytoin, 1%) and hypothyroidism (with evidence of improvement of the neuropathy with thyroid replacement alone; n = 3, 1%) were noted. One patient was found to have low vitamin B6 and improved with nutritional support; in another patient the neuropathy was thought to be related to sarcoidosis (confirmed by biopsy). Thus, a possible aetiology for the neuropathy was established in 75 patients, leaving 140 patients with seemingly idiopathic neuropathy. Positive serology for gluten sensitivity (IgG or IgA antigliadin antibodies) was found in 47 of 140 (34%) patients with idiopathic neuropathy. This compared with 12% prevalence of these antibodies in the control population of Sheffield.10The difference in prevalence of antigliadin antibodies between the two groups was significant (p<0.001 by χ2test). In addition, 7 of 75 (9%) patients with neuropathy of known aetiology (two with type 1 diabetes and five with low vitamin B12) were found to have antigliadin antibodies. Of the 47 patients with gluten sensitivity, 45 underwent duodenal biopsies and 12 (27%) were found to have an enteropathy in keeping with coeliac disease. Thus, the prevalence of coeliac disease as determined by biopsy in the idiopathic group was at least 9% (12/140). This compares with 1% prevalence of coeliac disease in the controls.9 Table 1​1 summarises these data.

Table thumbnail

Table 1 Causes of neuropathy in 215 patients with chronic axonal neuropathy

Clinical characteristics

The clinical and immunological characteristics of the 47 patients with gluten sensitivity and otherwise idiopathic neuropathy were then combined with those of 53 patients with gluten sensitivity and neuropathy who had been referred consecutively to the gluten sensitivity/neurology clinic from other neurologists from Sheffield and elsewhere in the UK. All the additional 53 patients were investigated in a similar manner and other causes of neuropathy were excluded. Table 2​2 outlines the clinical features of these 100 patients.

Table thumbnail

Table 2 Clinical and immunological characteristics of 100 patients with gluten neuropathy

The mean age at onset of the neuropathy was 55 (range 24–77) years, with a mean symptom duration of 9 (range 1–33) years. In all, 67 patients had a symmetrical generalised sensorimotor axonal neuropathy, 17 had mononeuropathy multiplex, 9 had pure motor neuropathy and 7 had small‐fibre neuropathy. Antigliadin IgG antibodies alone were positive in 57%, antigliadin IgA alone in 16%, and both IgG and IgA were positive in the remaining 27%. Tissue transglutaminase antibodies were present in 16 of 44 (36%) patients and antiendomysium antibodies in 12 of 52 (23%) patients who underwent these additional tests. Gluten‐sensitive enteropathy was present in 26 of 89 (29%) patients who underwent duodenal biopsy. The human leucocyte antigen (HLA) types associated with coeliac disease were seen in 80% (62% HLA‐DQ2, 10% HLA‐DQ8, 8% HLA‐DR3, HLA‐DR5 or HLA‐DR7, without HLA‐DQ2 or HLA‐DQ8) of these patients. The remaining had HLA‐DQ1. We found no significant differences in any of the above characteristics between the 47 patients from the prevalence study and the 53 patients referred from elsewhere.

Neuropathological findings

Pathological data were available from three patients (sural‐nerve biopsies in two patients and an autopsy in one).

A sural‐nerve biopsy from a 65‐year‐old man (positive antigliadin antibodies, normal duodenal biopsy) with clinical and neurophysiological evidence of sensorimotor axonal neuropathy showed a focal inflammatory cell infiltrate in the epineurium and around a small endoneurial blood vessel in one fascicle (fig 1​1).). The inflammatory cells, which included plasma cells, were closely related to the vessel wall. Resin‐embedded thin sections showed a patchy loss of myelinated fibres and occasional degenerating fibres. Occasional thinly myelinated fibres were seen, but not demyelinated fibres. These appearances suggested axonal degeneration secondary to an inflammatory microvasculopathy. The patient’s condition is stable while on a gluten‐free diet.

figure jn93534.f1

Figure 1 Sural‐nerve biopsy specimen from a 65‐year‐old man with gluten neuropathy, showing a focal inflammatory cell infiltrate in the epineurium and around a small endoneurial blood vessel (arrow, A). The inflammatory …

Case 2 was a 49‐year‐old man with asymmetrical sensorimotor axonal neuropathy suggestive of mononeuropathy multiplex. He had positive antigliadin antibodies, and coeliac disease was confirmed on duodenal biopsy. He had never been strict with his gluten‐free diet (persistently positive antigliadin antibodies) and the neuropathy had progressed. He underwent a fascicular sural‐nerve biopsy, containing a single fascicle. This showed evidence of axonal degeneration, but no evidence of inflammatory cell infiltration.

Case 3 was a 32‐year‐old woman who died from a rapidly progressive neuropathy (symmetrical sensorimotor axonal neuropathy) and ataxia, whose onset coincided with the diagnosis of gluten sensitivity. She also had evidence of enteropathy on biopsy. Autopsy showed inflammatory changes in both the central and the peripheral nervous systems (represented by spinal nerve roots). Capillaries in the brain seemed prominent in some areas, with hypertrophic endothelial cells. These vascular changes were most conspicuous in white matter, including cerebral, cerebellar and brain stem white matter. However, similar changes were seen focally in grey matter areas, including the hippocampus and the inferior olivary nucleus. The capillary changes were associated with a vascular and perivascular inflammatory cell infiltrate, predominantly of histiocytes (CD68+) and a lighter population of small lymphocytes, which were mostly T cells (CD45Ro+). Occasional fragmenting nuclei, possibly representing apoptotic bodies, were seen, but there was no vascular necrosis. We observed no tissue necrosis or microinfarction, and only mild focal myelin loss. Similar changes were also seen in the spinal cord. The cerebellum showed loss of Purkinje cells (fig 2A​2A)) with increased Bergmann glia, and there was a mild patchy loss of neurones in the inferior olivary nucleus. Spinal roots of peripheral nerve showed inflammatory cell infiltrate of both lymphocytes and macrophages (fig 2B​2B),), some of which were positive for T cell markers.

figure jn93534.f2

Figure 2 Cerebellum and peripheral nerve tissue obtained at autopsy from a 32‐year‐old woman who died from a rapidly progressive neuropathy and ataxia, the onset of which coincided with the diagnosis of gluten‐sensitive …
Go to:

Discussion

Demyelinating inflammatory neuropathies have been the focus of most research on peripheral neuropathies; yet axonal neuropathies are by far the most common type of neuropathies encountered in everyday neurological practice.12,13 This large prospective study has attempted to identify a prevalence figure (among patients with sporadic axonal neuropathy) and clinically characterise gluten sensitivity‐related neuropathy. Data on the prevalence of other causes of axonal neuropathies are also presented in this study, but are unlikely to represent the true prevalence of each aetiology in the general population because of referral bias. For example, in this study, diabetes accounted for 11% of all the neuropathies but was found to be the cause of neuropathy in >50% of patients in another study.12 In the UK, patients with established and poorly controlled diabetes who have a neuropathy are less likely to be referred to neurology clinics, given that the aetiology and treatment of their neuropathy is apparent. In this study for most patients with non‐insulin‐dependent diabetes, the diagnosis of diabetes was made on the basis of the aetiology of the neuropathy. The figures of prevalence for the different aetiologies of neuropathy found in this study reflect more closely what is seen in a long‐established general neurology clinic where patients with chronic axonal neuropathies are followed up long term.

The principal aim of this study was to investigate the prevalence of gluten sensitivity among patients with chronic idiopathic axonal neuropathy as defined by the presence of antigliadin antibodies. To avoid referral bias (in view of our interest in the neurological manifestations of gluten sensitivity), we deliberately excluded any patients referred to the gluten sensitivity/neurology clinic with an established diagnosis of gluten neuropathy. The prevalence of antigliadin antibody positivity was 34% in patients with otherwise idiopathic axonal neuropathy compared with 9% in patients with established cause of neuropathy and 12% in controls from the same region.10 The prevalence of coeliac disease among these patients was found to be at least 9% and compares with 1% in the controls from the same region.10 It is also possible that in those seven patients with neuropathy of known aetiology (two patients with type 1 diabetes and five patients with low vitamin B12) who also had antigliadin antibodies, the aetiology of the neuropathy could be linked to gluten sensitivity rather than to diabetes or low vitamin B12. We, however, found no correlation between vitamin B12deficiency and the presence of enteropathy.

A previous controlled study has shown that as many as 23% of patients with established coeliac disease on a gluten‐free diet showed axonal neuropathy on neurophysiological testing.8 Given that at least 1% of the healthy population in European countries and the US has coeliac disease and up to 12% has serological evidence suggestive of gluten sensitivity, such sensitivity may well prove to be a common aetiological link to chronic idiopathic axonal neuropathy.

Some clinicians choose to distinguish between those patients with gluten sensitivity who have an enteropathy (coeliac disease) and those without an enteropathy but with positive serological markers for gluten sensitivity. The rationale for this is not clear, as gluten sensitivity represents a spectrum ranging from antibody‐positive but normal small‐bowel mucosa (often referred to as potential coeliac disease or Marsh stage 01) to the presence of the classic small lesions on a biopsy sample, which define coeliac disease. The range of changes seen on examination of the small‐bowel mucosa, which may relate to gluten load, has been documented in detail and is now known as the Marsh classification.14 Thus, in the case of our patients with peripheral neuropathy associated with gluten sensitivity, there is nothing on clinical, genetic or immunological grounds to distinguish between patients with or without enteropathy. Extraintestinal manifestations can be the presenting feature of this disease (eg, dermatitis herpetiformis, gluten ataxia), and such manifestations can be successfully treated with a gluten‐free diet even in the absence of enteropathy.15 We therefore propose the term “gluten neuropathy” to describe this entity. Such a term encompasses patients with positive antigliadin antibodies with or without the bowel being affected (coeliac disease) and in the absence of an alternative aetiology for the neuropathy. The HLA type may offer additional diagnostic value, given that 80% of these patients have HLA‐DQ2 or HLA‐DQ8. Tissue transglutaminase and antiendomysium antibodies are good markers for the presence of an enteropathy (coeliac disease) but lack sensitivity when the bowel mucosa is normal and the disease presents with extraintestinal manifestations. Some patients reported in this study probably had a neuropathy that was coincidentally rather than aetiologically linked with the presence of circulating antigliadin antibodies. This is inevitable given that as yet there are no specific serological markers for the neurological spectrum of gluten sensitivity. Antigliadin antibodies currently remain the most sensitive markers of the whole spectrum of gluten sensitivity. The prospect of an additional marker seems imminent after the recent discovery that in vivo IgA deposits against tissue transglutaminase type 2 in the small‐bowel biopsy specimens of patients with diverse manifestations within the spectrum of gluten sensitivity are detected even in the absence of enteropathy. Such deposits have also been found in extraintestinal tissue, such as vessels in the cerebellum in patients with gluten ataxia. This marker seems to be highly specific for the whole spectrum of gluten sensitivity, as it was not found to be present in healthy and disease control subjects.16

The pathophysiology of gluten neuropathy remains unclear. Nutrient and vitamin deficiencies are unlikely to play a part, given that most of these patients have a normal nutritional status and no enteropathy. The mechanism is more likely to be immunological along the same lines as gluten ataxia.17 The pathology is that of an inflammatory process as outlined in this study and reported previously.7 This process can clearly affect peripheral nerves as well as the central nervous system.18,19,20 More often than not, however, the biopsy findings are those of axonal degeneration without evidence of inflammation. Patients with gluten sensitivity may rarely present with a rapidly progressive neuropathy, often associated with involvement of the central nervous system, as described for case 3 in Neuropathological findings. Such cases have previously been described by Cooke and Thomas‐Smith.20 On the basis of this study and the review of published case reports, the most common neuropathy encountered in the context of gluten sensitivity is that of a chronic slowly progressive symmetrical sensorimotor axonal distally predominant peripheral neuropathy. Further evidence in support of gluten neuropathy being immune mediated comes from a report on the presence of antiganglioside antibodies in patients with coeliac disease and neuropathy.21

Why the same disease (gluten sensitivity) results in both symmetrical and at times asymmetrical neuropathy (mononeuropathy multiplex), or even pure motor or sensory neuropathy remains unclear. This diverse pattern of peripheral nerve involvement is also seen in other diseases such as diabetes mellitus or neuropathy associated with connective tissue diseases. In one of our patients with gluten sensitivity, we observed progression of the motor neuropathy to involvement of sensory fibres with continuous exposure to gluten.22It is yet unclear whether the aetiology of the mononeuropathy multiplex seen in some of these patients with gluten sensitivity is mediated through a low‐grade vasculitic process.

We conclude that serological evidence of gluten sensitivity is commonly found in chronic idiopathic axonal neuropathies and may well be aetiologically linked. The effect of a gluten‐free diet on the neuropathy should confirm whether or not this is another manifestation of gluten sensitivity similar to gluten ataxia, dermatitis herpediformis and gluten‐sensitive enteropathy.

Go to:

Abbreviations

HLA – human leucocyte antigen

Go to:

Footnotes

Competing interests: None.

Ethical approval: The South Sheffield Research Ethics Committee approved the study protocol, and all patients provided written informed consent.

Go to:

References

1. Marsh M N. The natural history of gluten sensitivity: defining, refining and re‐defining. Q J Med 1995859–13. [PubMed]
2. Hadjivassiliou M, Grünewald R A. The neurology of gluten sensitivity: science vs. conviction. Pract Neurol 20044124–126.
3. Hadjivassiliou M, Grünewald R A, Sharrack B. et al Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 2003126685–691. [PubMed]
4. Holmes G K T. Neurological and psychiatric complications in coeliac disease. In: Gobbi G, Anderman F, Naccarato S, Banchini G, eds. Epilepsy and other neurological disorders in coeliac disease. London: John Libbey, 1997
5. Hadjivassiliou M, Grünewald R A, Davies‐Jones G A B. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 200272560–563. [PMC free article] [PubMed]
6. Hadjivassiliou M, Gibson A, Davies‐Jones G A B. et al Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996347369–371. [PubMed]
7. Hadjivassiliou M, Grünewald R A, Chattopadhyay A K. et al Clinical, radiological, neurophysiological and neuropathological characteristics of gluten ataxia. Lancet 19983521582–1585. [PubMed]
8. Luostarinen L, Himanen S L, Luostarinen M. et al Neuromuscular and sensory disturbances in patients with well treated coeliac disease. J Neurol Neurosurg Psychiatry 200374490–494. [PMC free article][PubMed]
9. Chin R L, Sander H W, Brannagan T H. et al Celiac neuropathy. Neurology 2003601581–1585.[PubMed]
10. Sanders D S, Patel D, Stephenson T J. et al A primary care cross‐sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol 200315407–413. [PubMed]
11. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardised report scheme for pathologists. Eur J Gastroenterol Hepatol 1999111185–1194. [PubMed]
12. Rosenberg N R, Portegies P, DeVisser M. et al Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry 200171205–209. [PMC free article] [PubMed]
13. Hughes R A C. Peripheral neuropathy. BMJ 2002324466–469. [PMC free article] [PubMed]
14. Marsh M N. Gluten, major histocompatibility complex, and the small intestine. Gastroenterology 1992102330–354. [PubMed]
15. Hadjivassiliou M, Davies‐Jones G A B, Sanders D S. et al Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003741221–1224. [PMC free article] [PubMed]
16. Hadjivassiliou M, Mäki M, Sanders D S. et al Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 200666373–377. [PubMed]
17. Hadjivassiliou M, Boscolo S, Davies‐Jones G A B. et al The humoral response in the pathogenesis of gluten ataxia. Neurology 2002581221–1226. [PubMed]
18. Muller A F, Donnelly M T, Smith C M L. et al Neurological complications of coeliac disease: a rare but continuing problem. Am J Gastroenterol 1996911430–1435. [PubMed]
19. Kelkar P, Ross M, Murray J. Mononeuropathy multiplex associated with celiac disease. Muscle Nerve 199619234–236. [PubMed]
20. Cooke W T, Thomas‐Smith W. Neurological disorders associated with adult celiac disease. Brain 196689683–722. [PubMed]
21. Alaedini A, Green P H R, Sander H W. et al Ganglioside reactive antibodies in the neuropathy associated with celiac disease. J Neuroimmunol 2002127145–148. [PubMed]
22. Hadjivassiliou M, Chattopadhyay A K, Davies‐Jones G A B. et al Neuromuscular disorder as a presenting feature of coeliac disease. J Neurol Neurosurg Psychiatry 199763770–775. [PMC free article][PubMed]

Biological Activities of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-Glucoside in Antiaging and Antiaging-Related Disease Treatments.

Biological Activities of 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-Glucoside in Antiaging and Antiaging-Related Disease Treatments.

Oxid Med Cell Longev. 2016;2016:4973239. doi: 10.1155/2016/4973239. Epub 2016 Jun 20.

 

Ling S1, Xu JW1.

Author information

Abstract

2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG) is active component of the Chinese medicinal plant Polygonum multiflorum Thunb. (THSG). Pharmacological studies have demonstrated that THSG exhibits numerous biological functions in treating atherosclerosis, lipid metabolism, vascular and cardiac remodeling, vascular fibrosis, cardiac-cerebral ischemia, learning and memory disorders, neuroinflammation, Alzheimer and Parkinson diseases, diabetic complications, hair growth problems, and numerous other conditions. This review focuses on the biological effects of THSG in antiaging and antiaging-related disease treatments and discusses its molecular mechanisms.

PMID:
27413420
PMCID:
PMC4931083
DOI:
10.1155/2016/4973239
[Indexed for MEDLINE]

Free PMC Article

Images from this publication.See all images (2)Free text 
Figure 1
Figure 2

Antibacterial and antifungal activity of ten essential oils in vitro

Microbios. 1996;86(349):237-46.
Pattnaik S1, Subramanyam VR, Kole C.
Image result for essential oils

The essential oils of aegle, ageratum, citronella, eucalyptus, geranium, lemongrass, orange, palmarosa, patchouli and peppermint, were tested for antibacterial activity against 22 bacteria, including Gram-positive cocci and rods and Gram-negative rods, and twelve fungi (3 yeast-like and 9 filamentous) by the disc diffusion method. Lemongrass, eucalyptus, peppermint and orange oils were effective against all the 22 bacterial strains. Aegle and palmarosa oils inhibited 21 bacteria; patchouli and ageratum oils inhibited 20 bacteria and citronella and geranium oils were inhibitory to 15 and 12 bacterial strains, respectively. All twelve fungi were inhibited by seven oils (aegle, citronella, geranium, lemongrass, orange, palmarosa and patchouli). Eucalyptus and peppermint oils were effective against eleven fungi. Ageratum oil was inhibitory to only four fungi tested. The MIC of eucalyptus, lemongrass, palmarosa and peppermint oils ranged from 0.16 to > 20 microliters ml-1 for eighteen bacteria and from 0.25 to 10 microliters ml-1 for twelve fungi.

PMID:

 

941-444-6336 Directions